New pill targets Hard-to-Treat KRAS cancers in first human trial
NCT ID NCT07094113
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new oral drug called AMG 410, alone or with other medicines, in adults with advanced solid tumors that have KRAS gene changes. The study aims to find a safe dose and check for side effects. About 434 participants will take part across multiple dose levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AMG 410 (oral tablet), pembrolizumab (IV infusion), panitumumab (IV infusion)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced cancers that have KRAS mutations, especially those who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial, so the drug may not work or may cause serious side effects. The study is primarily looking at safety and dosing, not yet proving effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS ALTERED ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center
RECRUITINGNagoya, Aichi-ken, 464-8681, Japan
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
Azienda Ospedaliero Universitaria Pisana
RECRUITINGPisa, 56126, Italy
-
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
RECRUITINGMilan, 20162, Italy
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Centre Leon Berard
RECRUITINGLyon, 69008, France
-
Centro Ricerche Cliniche Di Verona Societa responsabilita limitata
RECRUITINGVerona, 37134, Italy
-
Chris OBrien Lifehouse
RECRUITINGCamperdown, New South Wales, 2050, Australia
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Duke Cancer Center
RECRUITINGDurham, North Carolina, 27710, United States
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
-
Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Jinan Central Hospital
RECRUITINGJinan, Shandong, 250013, China
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa-shi, Chiba, 277-8577, Japan
-
Next Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
Next Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 1Z5, Canada
-
Rigshospitalet
RECRUITINGCopenhagen, 2100, Denmark
-
Royal Marsden Hospital
RECRUITINGSutton, SM2 5PT, United Kingdom
-
Sarah Cannon Research Institute Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute UK
RECRUITINGLondon, W1G 6AD, United Kingdom
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Sir Mortimer B Davis - Jewish General Hospital
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
-
Siteman Cancer Center - Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
-
The Queen Elizabeth Hospital
RECRUITINGWoodville South, South Australia, 5011, Australia
-
Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
Universitaetsklinikum Essen
RECRUITINGEssen, 45147, Germany
-
Universitair Medisch Centrum Utrecht
RECRUITINGUtrecht, 3584 CX, Netherlands
-
Universitair Ziekenhuis Antwerpen
RECRUITINGEdegem, 2650, Belgium
-
Universitair Ziekenhuis Gent
RECRUITINGGhent, 9000, Belgium
-
University of California Los Angeles
RECRUITINGLos Angeles, California, 90095, United States